Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Ref Type | |||||||||||||
PMID | |||||||||||||
Authors | David A. Reardon, Tae-Min Kim, Jean-Sebastien Frenel, Armando Santoro, Juanita Lopez, Deepa S. Subramaniam, Lillian L. Siu, Jordi Rodon, Kenji Tamura, Sanatan Saraf, Anne Morosky, Karen Stein and Jean-Charles Soria | ||||||||||||
Title | RESULTS OF THE PHASE IB KEYNOTE-028 MULTI-COHORT TRIAL OF PEMBROLIZUMAB MONOTHERAPY IN PATIENTS WITH RECURRENT PD-L1-POSITIVE GLIOBLASTOMA MULTIFORME (GBM) | ||||||||||||
|
|||||||||||||
URL | http://neuro-oncology.oxfordjournals.org/content/18/suppl_6/vi25.4.abstract?sid=af283a96-f950-4f1d-a7cb-611b9ddd3325 | ||||||||||||
Abstract Text | Neuro Oncol (2016) 18 (suppl 6): vi25-vi26. |
Molecular Profile | Treatment Approach |
---|
Gene Name | Source | Synonyms | Protein Domains | Gene Description | Gene Role |
---|
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|
Gene | Variant | Impact | Protein Effect | Variant Description | Associated with drug Resistance |
---|
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
CD274 positive | glioblastoma | conflicting | Pembrolizumab | Phase Ib/II | Actionable | In a Phase Ib trial, Keytruda (pembrolizumab) treatment resulted in partial response in 4% (1/25), stable disease in 48% (12/25), a median progression free survival of 2.8 months, and a median overall survival of 14.4 months in patients with CD274 (PD-L1) positive, bevacizumab-naive recurrent glioblastoma (Neuro Oncol (2016) 18 (suppl 6): vi25-vi26.). | detail... |